<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726215</url>
  </required_header>
  <id_info>
    <org_study_id>CST-FARAG-IO-MULT-201</org_study_id>
    <nct_id>NCT04726215</nct_id>
  </id_info>
  <brief_title>Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer</brief_title>
  <official_title>Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellSight Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellSight Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study using [18F]F AraG PET imaging to evaluate the immunological response to&#xD;
      checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study&#xD;
      sites. The main objectives of the study are to quantify the change in [18F]F AraG PET signal&#xD;
      before and after CkIT therapy, and to correlate this change in [18F]F AraG PET signal with a&#xD;
      radiographic response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50 patients will undergo two research PET/CT scans with [18F]F AraG at two time&#xD;
      points. Each patient will receive two 5 (+/-10%) mCi doses of [18F]F AraG, one for each&#xD;
      imaging time point. Eligible subjects will undergo a pre-treatment [18F]F AraG PET/CT scan&#xD;
      within 7 days prior to treatment, followed by treatment, and an on-treatment [18F]F AraG&#xD;
      PET/CT within 7-14 days of treatment.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Quantify [18F]F-AraG uptake in advanced NSCLC tumor (primary, nodal, and metastatic&#xD;
           sites) at baseline and after 1 dose of anti-PD-1/PD-L1 therapy in patients treated with&#xD;
           standard of care immunotherapy (as monotherapy or part of combination therapy).&#xD;
&#xD;
        -  Correlate change in [18F]F AraG uptake in tumor lesions with radiographic response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">May 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[18F]F-AraG uptake signal</measure>
    <time_frame>two years</time_frame>
    <description>[18F]F-AraG uptake signal will be measured quantitatively by SUV-bw of the tumor volumes of interest before and after undergoing treatment</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]F AraG</intervention_name>
    <description>PET imaging agent specific to activated T cells</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a histologically confirmed NSCLC and planned to undergo immunotherapy as&#xD;
             monotherapy or as combination therapy with concurrent as treatment for&#xD;
             advanced/metastatic disease.&#xD;
&#xD;
          2. RECIST measurable disease.&#xD;
&#xD;
          3. ECOG performance status of 0, 1 or 2.&#xD;
&#xD;
          4. Life expectancy &gt;/= 6 months at enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious comorbidities that in the opinion of the investigator/sponsor could compromise&#xD;
             protocol objectives.&#xD;
&#xD;
          2. Pregnant women or nursing mothers.&#xD;
&#xD;
          3. Patients with severe claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak Behera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CellSight Technologies, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SAMUEL QUEZADA</last_name>
    <phone>6507991589</phone>
    <email>squezada@cellsighttech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Guillen Guillen</last_name>
      <phone>916-887-4656</phone>
      <email>GuilleM1@sutterhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lori Pruski-Clark</last_name>
      <phone>916-453-5807</phone>
    </contact_backup>
    <investigator>
      <last_name>Deepti Behl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermina Munoz</last_name>
      <phone>631-216-2990</phone>
      <email>Hermina.Munoz@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Roger Keresztes, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

